Is It Possible to Have Cheaper Drugs and Preserve the Incentive to Innovate: Reforming the Drug Approval Process According to Market Principles
This paper argues that drugs are expensive not because of a lack of competition among research-based pharmaceutical companies, but because of a lack of competition in the drug approval process. Lack of competition in the drug approval process has led to exceedingly high drug development costs. High drug development costs combined with artificially low drug prices, obtained through price control legislation and legislation that eases the entry of generic products into the market, has caused lower levels of pharmaceutical research and development, innovation, and economic growth.
|Date of creation:||Jun 2005|
|Date of revision:|
|Publication status:||Published in Journal of Technology Transfer, 2007, 32(5), pages 509-524.|
|Contact details of provider:|| Web page: http://www.jims-israel.org|
More information through EDIRC
When requesting a correction, please mention this item's handle: RePEc:jms:wpaper:5. See general information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Corinne Sauer)
If references are entirely missing, you can add them using this form.